Fiera Capital Corp Viking Therapeutics, Inc. Transaction History

Fiera Capital Corp

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Aug 22, 2024	BUY	$10.92 - $16.0 $574,981 - $842,464	52,654 New	52,654 $582,000
Q4 2021 Feb 08, 2022	SELL	$4.6 - $6.72 $4.68 Million - $6.83 Million	-1,016,356 Reduced 95.07%	52,654 $242,000
Q3 2021 Nov 12, 2021	SELL	$5.58 - $7.04 $91,433 - $115,357	-16,386 Reduced 1.51%	1,069,010 $6.71 Million
Q2 2021 Aug 11, 2021	SELL	$5.19 - $6.73 $155,803 - $202,034	-30,020 Reduced 2.69%	1,085,396 $7.83 Million
Q1 2021 May 11, 2021	BUY	$5.74 - $9.67 $49,111 - $82,736	8,556 Added 0.77%	1,115,416 $7.06 Million
Q4 2020 Feb 09, 2021	SELL	$5.3 - $6.71 $110,732 - $140,192	-20,893 Reduced 1.85%	1,106,860 $6.23 Million
Q3 2020 Nov 12, 2020	SELL	$5.73 - $8.11 $213,941 - $302,803	-37,337 Reduced 3.2%	1,127,753 $6.56 Million
Q2 2020 Aug 07, 2020	SELL	$4.35 - $8.08 $110,581 - $205,401	-25,421 Reduced 2.14%	1,165,090 $8.4 Million
Q1 2020 May 08, 2020	SELL	$3.45 - $7.95 $21,759 - $50,140	-6,307 Reduced 0.53%	1,190,511 $5.57 Million
Q4 2019 Feb 06, 2020	SELL	$6.38 - $8.73 $693,971 - $949,588	-108,773 Reduced 8.33%	1,196,818 $9.6 Million
Q3 2019 Nov 12, 2019	SELL	$6.55 - $8.6 $229,046 - $300,733	-34,969 Reduced 2.61%	1,305,591 $8.98 Million
Q2 2019 Aug 12, 2019	SELL	$7.67 - $10.63 $625,818 - $867,333	-81,593 Reduced 5.74%	1,340,560 $11.1 Million
Q1 2019 May 10, 2019	SELL	$7.58 - $9.94 $285,167 - $373,952	-37,621 Reduced 2.58%	1,422,153 $14.1 Million
Q4 2018 Feb 12, 2019	BUY	$7.16 - $16.21 $10.5 Million - $23.7 Million	1,459,774 New	1,459,774 $11.2 Million

442

63.3M

6.23M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.83B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Fiera Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Fiera Capital Corp with notifications on news.